PANULISIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H20F3N9
Molecular Weight	527.5032
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C2=C(N(\C1=N\C#N)C3=CN=C(C=C3)C(C)(C)C#N)C4=CC(=CC=C4N=C2)C5=CN=C(N)C(=C5)C(F)(F)F

InChI

InChIKey=VJLRLTSXTLICIR-AUGOTPMTSA-N

InChI=1S/C27H20F3N9/c1-26(2,13-31)22-7-5-17(11-35-22)39-23-18-8-15(16-9-19(27(28,29)30)24(33)36-10-16)4-6-20(18)34-12-21(23)38(3)25(39)37-14-32/h4-12H,1-3H3,(H2,33,36)/b37-25+

HIDE SMILES / InChI

Molecular Formula	C27H20F3N9
Molecular Weight	527.5032
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT01762410 | https://www.ncbi.nlm.nih.gov/pubmed/25700704

Panulisib (P7170) was developed as a small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR with potential anticancer activity. It is known that mTOR pathway is often upregulated in cancer and thus intensively pursued as a target to design novel anticancer therapies. P7170 were being tested in phase I clinical studies in patients with advanced refractory solid tumors. The primary objective was to determine the maximum tolerated dose and dose-limiting toxicity of the drug. However, this study is suspended because of the sponsor’s decision.

Approval Year

PubMed

Title	Date	PubMed
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.	2014 Dec 2	25466244
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.	2015 Jan	25491778
P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.	2015 May	25700704

Patents

Sample Use Guides

In Vivo Use Guide

Patients will receive orally study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:40:37 GMT 2023` Edited by `admin` on `Sat Dec 16 05:40:37 GMT 2023`
Record UNII	S9WA04F921
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PANULISIB

Official Name

English

CYANAMIDE, N-(8-(6-AMINO-5-(TRIFLUOROMETHYL)-3-PYRIDINYL)-1-(6-(1-CYANO-1-METHYLETHYL)-3-PYRIDINYL)-1,3-DIHYDRO-3-METHYL-2H-IMIDAZO(4,5-C)QUINOLIN-2-YLIDENE)-

Systematic Name

English

Panulisib [WHO-DD]

Common Name

English

panulisib [INN]

Common Name

English

P-7170

Code

English

Code System Code Type Description

INN

9790